This NCD Academy course developed by MedShr with the American College of Cardiology delivers a structured educational program for doctors and healthcare professionals focused on the secondary prevention of cardiovascular disease (CVD): the actions required to reduce recurrent events, hospitalisation, and premature mortality.

Aligned with contemporary guidance from the American College of Cardiology / American Heart Association, the course translates evidence into practical, implementable clinical decision-making across the full patient pathway – from post-event optimisation to long-term risk management.

A central theme is that secondary prevention remains incomplete without both optimal medical therapy and structured lifestyle intervention, delivered through systems such as cardiac rehabilitation.

Educational Objectives

This course is designed to deliver measurable improvements in:

Knowledge: Understanding of guideline-directed secondary prevention strategies across lipid management, antithrombotic therapy, risk factor control, and lifestyle intervention

Competence: Ability to apply evidence-based therapies in real-world cases, including escalation decisions and risk stratification

Performance: Implementation of key actions in practice, including optimisation of medications, referral to cardiac rehabilitation, and delivery of behaviour change interventions

Course Faculty

Senior Editor

Dr Asif Qasim - Consultant Cardiologist at King's College Hospital and Cleveland Clinic London, UK.

Editors

Dr Miguel Alvarez - Director of Interventional Heart Failure at Lennox Hill Hospital, New York, USA.

Dr Adhir Shroff - Chief of Service for Cardiology, University of Illinois School of Medicine, Chicago, USA

Disclosures

The NCD Academy is supported by educational grant funding to the American College of Cardiology Foundation from Viatris. The company has no control of the content of this independent medical education program.

There are no relevant disclosures for the Faculty in relation to pharmaceutical and other ineligible companies as defined by ACCME.